Delayed treatment safe for some people with diabetic eye disease

Health news

NewYork. People with diabetes may develop a problem in their eyes called diabetic macular edema. This is a swelling or thickening of the macula, an area in the center of the retina—the part of the eye that senses light. It’s caused by damage to the small blood vessels of the retina. Diabetic macular edema is the most common cause of vision loss among people with diabetes.

If doctors
detect vision loss caused by diabetic macular edema early, treatment can slow
or stop it. But it hasn’t been clear if treatment should be given to people
with diabetic macular edema who still have good vision.

To better
understand the appropriate timing for treatment, a team led by Dr. Carl Baker
from the Paducah Retinal Center in Kentucky enrolled about 700 people into a
clinical trial. All participants had diabetic macular edema but still had
normal or near-normal vision. The team randomly assigned participants to three

One group
received injections into the eye of a drug that prevents vision loss. The
second group underwent a treatment called photocoagulation, which uses
lasers to seal leaky blood vessels in the eye. The third group received no
immediate treatment, but had their eyes checked at eight and 16 weeks after
study entry, and then every 16 weeks. If vision loss began to develop in
participants in this group over two years of follow-up, they immediately began
drug injections.

The study was funded by NIH’s National Eye Institute (NEI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Results were published on April 29, 2019, in JAMA.

Due to progressive vision loss, 25% of people in the photocoagulation group and 34% of people in the observation group started drug injections. At the end of the study, rates of vision loss were about the same between the three groups, regardless of what treatment they started with. After two years, the average vision was 20/20 in all groups—the same as at the start of the study (Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.).

Increases in pressure within the eye were more common in the drug injection group than in the observation group. Other side effects did not differ between the groups.

“We now know
that in patients with good vision and diabetic macular edema, similar to those
enrolled in this trial, it’s an acceptable strategy to closely monitor
patients, and initiate treatment only if their vision starts to show signs of
decline,” Baker says.

Participants in the trial had good control of their blood sugar, which helps prevent diabetic eye disease, and came in for regular checkups. The researchers caution that delaying treatment may not be as safe for people who have trouble managing their blood sugar or coming in for regular eye exams.

हमें गूगल न्यूज पर फॉलो करें. ट्विटर पर फॉलो करें. वाट्सएप पर संदेश पाएं. हस्तक्षेप की आर्थिक मदद करें

Enter your email address:

Delivered by FeedBurner